These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18290726)

  • 1. Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells.
    Penna G; Amuchastegui S; Laverny G; Adorini L
    J Bone Miner Res; 2007 Dec; 22 Suppl 2():V69-73. PubMed ID: 18290726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intervention in autoimmunity: the potential of vitamin D receptor agonists.
    Adorini L
    Cell Immunol; 2005 Feb; 233(2):115-24. PubMed ID: 15936743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tolerogenic dendritic cells by vitamin D receptor agonists.
    Adorini L; Penna G
    Handb Exp Pharmacol; 2009; (188):251-73. PubMed ID: 19031030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands.
    Adorini L; Penna G; Giarratana N; Roncari A; Amuchastegui S; Daniel KC; Uskokovic M
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):437-41. PubMed ID: 15225816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases.
    Adorini L; Penna G; Giarratana N; Uskokovic M
    J Cell Biochem; 2003 Feb; 88(2):227-33. PubMed ID: 12520519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of autoimmune diseases by the vitamin D endocrine system.
    Adorini L; Penna G
    Nat Clin Pract Rheumatol; 2008 Aug; 4(8):404-12. PubMed ID: 18594491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.
    Sochorová K; Budinský V; Rozková D; Tobiasová Z; Dusilová-Sulková S; Spísek R; Bartůnková J
    Clin Immunol; 2009 Oct; 133(1):69-77. PubMed ID: 19660988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists.
    Adorini L; Penna G
    Hum Immunol; 2009 May; 70(5):345-52. PubMed ID: 19405173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells.
    Adorini L; Giarratana N; Penna G
    Semin Immunol; 2004 Apr; 16(2):127-34. PubMed ID: 15036236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.
    Kavousanaki M; Makrigiannakis A; Boumpas D; Verginis P
    Arthritis Rheum; 2010 Jan; 62(1):53-63. PubMed ID: 20039433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis.
    Iruretagoyena MI; Sepúlveda SE; Lezana JP; Hermoso M; Bronfman M; Gutiérrez MA; Jacobelli SH; Kalergis AM
    J Pharmacol Exp Ther; 2006 Jul; 318(1):59-67. PubMed ID: 16597709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases.
    Adorini L
    Int Immunopharmacol; 2002 Jun; 2(7):1017-28. PubMed ID: 12188026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells modified by vitamin D: future immunotherapy for autoimmune diseases.
    Pedersen AW; Claesson MH; Zocca MB
    Vitam Horm; 2011; 86():63-82. PubMed ID: 21419267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerogenic dendritic cells for autoimmune disease and transplantation.
    Thomson AW; Robbins PD
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii90-6. PubMed ID: 19022823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D receptor ablation alters skin architecture and homeostasis of dendritic epidermal T cells.
    Meindl S; Rot A; Hoetzenecker W; Kato S; Cross HS; Elbe-Bürger A
    Br J Dermatol; 2005 Feb; 152(2):231-41. PubMed ID: 15727633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells.
    Penna G; Amuchastegui S; Giarratana N; Daniel KC; Vulcano M; Sozzani S; Adorini L
    J Immunol; 2007 Jan; 178(1):145-53. PubMed ID: 17182549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of chronic allograft rejection by Vitamin D receptor agonists.
    Adorini L; Amuchastegui S; Daniel KC
    Immunol Lett; 2005 Aug; 100(1):34-41. PubMed ID: 16054704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D endocrine system and the immune response in rheumatic diseases.
    Cutolo M; Plebani M; Shoenfeld Y; Adorini L; Tincani A
    Vitam Horm; 2011; 86():327-51. PubMed ID: 21419278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells.
    Mascarell L; Lombardi V; Louise A; Saint-Lu N; Chabre H; Moussu H; Betbeder D; Balazuc AM; Van Overtvelt L; Moingeon P
    J Allergy Clin Immunol; 2008 Sep; 122(3):603-9.e5. PubMed ID: 18774396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype.
    Széles L; Keresztes G; Töröcsik D; Balajthy Z; Krenács L; Póliska S; Steinmeyer A; Zuegel U; Pruenster M; Rot A; Nagy L
    J Immunol; 2009 Feb; 182(4):2074-83. PubMed ID: 19201860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.